Fluocinolone acetonide; neomycin sulfate - Generic Drug Details

What are the generic drug sources for fluocinolone acetonide; neomycin sulfate and what is the scope of patent protection?

Fluocinolone acetonide; neomycin sulfate is the generic ingredient in one branded drug marketed by Eurofarma and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for fluocinolone acetonide; neomycin sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	fluocinolone acetonide; neomycin sulfate at DailyMed

Recent Clinical Trials for fluocinolone acetonide; neomycin sulfate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Noah Rosenberg, MD	Phase 4

See all fluocinolone acetonide; neomycin sulfate clinical trials

Pharmacology for fluocinolone acetonide; neomycin sulfate

Drug Class	Aminoglycoside Antibacterial Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for fluocinolone acetonide; neomycin sulfate

A01AB	Antiinfectives and antiseptics for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

B05CA	Antiinfectives
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

J01GB	Other aminoglycosides
J01G	AMINOGLYCOSIDE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

R02AB	Antibiotics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02BA	Corticosteroids
S02B	CORTICOSTEROIDS
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for fluocinolone acetonide; neomycin sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eurofarma	NEO-SYNALAR	fluocinolone acetonide; neomycin sulfate	CREAM;TOPICAL	060700-001	Approved Prior to Jan 1, 1982		RX	No	Yes

Market Dynamics and Financial Trajectory for Fluocinolone Acetonide and Neomycin Sulfate

Last updated: February 20, 2026

Are there current market drivers influencing fluocinolone acetonide and neomycin sulfate?

Fluocinolone acetonide and neomycin sulfate are topical formulations used primarily to treat inflammatory skin conditions and bacterial infections, respectively. Their market growth depends on several factors:

• Increased prevalence of dermatological diseases, including psoriasis and eczema, boosts demand.
• Rising antibiotic resistance influences the use of combination drugs, like formulations combining corticosteroids and antibiotics.
• Patent status changes and new formulations can open or close market opportunities.
• Regulatory approvals impact market access; rights expiration of key patents introduces generic competition.
• Growing aging populations need chronic skin condition management, expanding the market.
• The COVID-19 pandemic temporarily disrupted supply chains but also increased demand for topical dermatological treatments.

How do market sizes and sales trends look for these drugs?

Fluocinolone Acetonide

• Estimated global market size: $400 million in 2022.
• Projected Compound Annual Growth Rate (CAGR): 4-6% through 2027.
• Key markets: United States, Europe, emerging markets in Asia-Pacific.
• Major formulations: topical ointments and creams, with some depot injections for specific indications.

Neomycin Sulfate

• Estimated global market size: $250 million in 2022.
• CAGR forecast: approximately 3-5% over the next five years.
• Utilized in combination with other antibiotics (e.g., polymyxin B), broadening application scope.
• Top markets include North America, Europe, and Asia-Pacific.

Market share and competitive landscape

Drug	Patent Status	Key Competitors	Generics Availability
Fluocinolone acetonide	Patent expired in major markets (e.g., US 2020)	Sandoz, Mylan, Dr. Reddy's	Yes
Neomycin sulfate	Patent expired long ago	Local generics manufacturers	Yes

What are the financial implications of patent expirations and generics?

Patent expirations have led to price reductions of approximately 50-60% for branded drugs. Entry of generics drives volume growth but compresses margins. For instance, the U.S. patent for fluocinolone acetonide ointments expired in 2020, resulting in increased generic penetration.

Revenue projections post-generic entry show a decline of up to 40% in branded market sales but compensate through increased volume. Companies investing in formulation improvements or combination therapies can offset margin erosion.

How does the regulatory environment influence market and financial outcomes?

Regulatory agencies like the FDA and EMA approve both new formulations and generics. Accelerated approvals for biosimilars and combination products can open new revenue streams. Conversely, stringent labeling or safety requirements can delay launches.

Market access is influenced by formulary inclusion, reimbursement policies, and pricing regulations. Cost-effectiveness assessments drive reimbursement decisions, impacting sales.

What are the key risks and opportunities?

Risks

• Price erosion due to generic entry.
• Regulatory delays or safety concerns.
• Competition from biosimilars or novel therapies.
• Market saturation in mature regions.

Opportunities

• Development of fixed-dose combination products.
• Expansion into emerging markets with unmet needs.
• Differentiation through innovative formulations (e.g., sustained-release).
• Patent extensions via new indications or delivery systems.

What are the projected financial trajectories?

By 2027, the combined market for fluocinolone acetonide and neomycin sulfate is expected to reach approximately $650-700 million globally, driven by growth in emerging markets and product line extensions. Branded sales will decline post-patent expiry, but overall revenue will be sustained through increased volume and new product launches.

The following aspects influence financial trajectories:

• Timing of patent expirations.
• Success of pipeline products.
• Market penetration of generics.
• Strategic licensing and partnerships.

Key Takeaways

• The market is growing modestly, influenced by demographic trends and new formulations.
• Patent expirations have led to significant price reductions but created opportunities for generics.
• Competition is intense, with major generic producers dominating in mature markets.
• Opportunities exist in combination therapies and emerging markets.
• Financial gains depend on the ability to innovate and adapt to regulatory changes.

FAQs

1. When did patents for fluocinolone acetonide expire in key markets?

Patents expired between 2019 and 2022, depending on the jurisdiction. The U.S. patent expired in 2020, prompting increased generic competition.

2. What are the primary drivers of demand for neomycin sulfate?

Demand stems from its extensive use in topical antibiotics, especially in combination formulas, and the rise of skin infections requiring effective treatments.

3. How does patent expiry affect pricing strategies?

Patent expiry typically causes prices to fall by 50-60%, prompting companies to focus on differentiating formulations or expanding into less saturated markets.

4. What regulatory challenges exist for these drugs?

Safety labeling updates, new formulation approvals, and biosimilar regulation can delay launches or impact sales.

5. Which markets show the highest growth potential?

Emerging markets in Asia-Pacific and Latin America offer considerable opportunity due to increasing healthcare access and rising dermatological conditions.

---

References

[1] Global Data. (2022). Market analysis of topical dermatological products.
[2] IQVIA. (2023). Pharmaceuticals market insights.
[3] U.S. Food and Drug Administration. (2021). Patent expiry reports.
[4] European Medicines Agency. (2022). Regulatory guidelines for topical therapies.
[5] MarketsandMarkets. (2022). Dermatology drugs market forecast.